Kira Pharmaceuticals is a clinical-stage, global biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline of nine (9) novel complement assets focused on validated targets across the complement cascade. With an experienced team of complement biology experts, drug developers, protein engineers and leaders from across the pharma and biotech industry, Kira Pharmaceuticals is uniquely positioned to tackle some of the most complex and toughest challenges in the complement space and to deliver first-in-class and best-in-class therapies to transform the lives of patients. The company is headquartered in Cambridge, Massachusetts with offices in Suzhou and Shanghai, China, and Australia.